login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PROMIS NEUROSCIENCES INC (PMN) Stock News
USA
-
Nasdaq
- NASDAQ:PMN -
CA74346M4065
-
Common Stock
7.62
USD
-0.29 (-3.61%)
Last: 12/8/2025, 8:00:00 PM
7.85
USD
+0.23 (+3.02%)
After Hours:
12/8/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PMN Latest News, Press Relases and Analysis
All
Press Releases
15 days ago - By: Chartmill
- Mentions:
SUPX
CMCT
CAPR
ENLV
...
Which stocks are experiencing notable movement on Monday?
15 days ago - By: Chartmill
- Mentions:
SUPX
CMCT
CAPR
MBRX
...
Top movers in Monday's session
8 days ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
8 days ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
8 days ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
15 days ago - By: Chartmill
- Mentions:
BFLY
INSP
SUPX
TE
...
The market is filled with gapping stocks in Monday's session.
15 days ago - By: Chartmill
- Mentions:
NVO
INSP
VIV
ENLV
...
Wondering what's happening in today's pre-market session?
15 days ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Reverse Stock Split
15 days ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Reverse Stock Split
20 days ago - By: Benzinga
- Mentions:
PHAR
AGIO
KZIA
CUE
...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
a month ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
a month ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
a month ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
a month ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
2 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
3 months ago - By: Benzinga
- Mentions:
MEIP
IMCC
SSKN
GNPX
...
12 Health Care Stocks Moving In Friday's After-Market Session
3 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
3 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
4 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
4 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
4 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
4 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
4 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
4 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
5 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
5 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces Private Placement Financing
5 months ago - By: ProMIS Neurosciences Inc.
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
Please enable JavaScript to continue using this application.